This corporate presentation was recorded during “Cancer Immunotherapy: A Long Awaited Reality”, a conference hosted by BioBusiness.TV and MD Becker Partners on October 21st, 2010, at the New York Academy of Medicine.
Featuring :
- Marnix L Bosch, PhD, Chief Technical Officer, Northwest Bioterapeutics, Inc., (OTC:NWBO)
Disclaimer :
TThis communication is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part; copies circulated, or disclosed to another party, without the prior written consent of Northwest Biotherapeutics (NWBT) are strictly prohibited.
Information and opinions presented in this report have been obtained or derived from sources believed to be reliable, but NWBT makes no representation as to their accuracy or completeness. NWBT accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to NWBT. This report is not to be relied upon in substitution for the exercise of independent judgment. NWBT may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods applicable when made, and NWBT is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report. All prices and costs mentioned in this report are subject to market conditions.
Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.
Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by NWBT, and are subject to change without notice. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. Securities offered or sold by NWBT: (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of principal invested. Additional information about NWBT can be found on the company’s website: www.nwbio.com.
Related Videos:
- ImmunoCellular Therapeutics Presentation at Cancer Immunotherapy Conference
- Celldex Presentation at Cancer Immunotherapy Conference
- Dendreon Presentation at Cancer Immunotherapy Conference
- Provectus Presentation at Cancer Immunotherapy Conference
- Vaccinogen Presentation at Cancer Immunotherapy Conference
- Inovio Presentation at Cancer Immunotherapy Conference
- Bavarian Presentation at Cancer Immunotherapy Conference
- BioSante Presentation at Cancer Immunotherapy Conference
- Biovest International Presentation at Cancer Immunotherapy Conference
- Argos Therapeutics Presentation at Cancer Immunotherapy Conference
One Trackback
[...] Northwest Biotherapeutics [...]